Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
SJ Thomas, ED Moreira Jr, N Kitchin… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA
vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory …
vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory …
Six Month safety and efficacy of the BNT162b2 Mrna Covid-19 vaccine
SJ Thomas, ED Moreira Jr, N Kitchin, J Absalon… - MedRxiv, 2021 - medrxiv.org
Background BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein …
encoding a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein …
BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting
Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19)
commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes …
commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes …
RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study
EE Walsh, R Frenck, AR Falsey, N Kitchin, J Absalon… - Medrxiv, 2020 - medrxiv.org
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and
the resulting disease, coronavirus disease 2019 (COVID-19), have spread to millions of …
the resulting disease, coronavirus disease 2019 (COVID-19), have spread to millions of …
Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
Background Preapproval trials showed that messenger RNA (mRNA)–based vaccines
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety …
Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
EE Walsh, RW Frenck Jr, AR Falsey… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and
the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
BNT162b2 mRNA COVID-19 vaccine: first approval
YN Lamb - Drugs, 2021 - Springer
Abstract BNT162b2 (Comirnaty®; BioNTech and Pfizer) is a lipid nanoparticle-formulated,
nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease …
nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease …
Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
O Magen, JG Waxman, M Makov-Assif… - … England Journal of …, 2022 - Mass Medical Soc
Background With large waves of infection driven by the B. 1.1. 529 (omicron) variant of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of …
Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine
ED Moreira Jr, N Kitchin, X Xu… - New England journal …, 2022 - Mass Medical Soc
Background Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a
critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV …